From the *Division of Nuclear Medicine, Department of Radiology, and †Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
Clin Nucl Med. 2014 Jan;39(1):e93-6. doi: 10.1097/RLU.0b013e318292a775.
Anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody therapy is a new class of drug which has demonstrated increased overall survival in patients with metastatic melanoma. Anti-CTLA-4 antibody therapy inhibits the CTLA-4 inhibitory signal, thereby enhancing the anti-tumor response of the cytotoxic T lymphocytes. This response can lead to a variety of immune-related adverse events. Many of these events are present on follow-up PET/CT examinations performed to assess response to therapy. It is important for the interpreting physician to be aware of the findings on PET/CT to avoid diagnosing adverse events as progressive disease and to alert clinicians regarding these complications.
抗细胞毒性 T 淋巴细胞相关抗原 4 单克隆抗体治疗是一类新药，已证明可提高转移性黑色素瘤患者的总生存率。抗 CTLA-4 抗体治疗抑制 CTLA-4 抑制信号，从而增强细胞毒性 T 淋巴细胞的抗肿瘤反应。这种反应可导致多种免疫相关不良事件。这些事件中的许多事件都存在于后续进行的 PET/CT 检查中，以评估对治疗的反应。对于解释医生来说，了解 PET/CT 的结果非常重要，以避免将不良事件误诊为进行性疾病，并提醒临床医生注意这些并发症。
